Comparative Pharmacology
Head-to-head clinical analysis: MIBELAS 24 FE versus OVULEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MIBELAS 24 FE versus OVULEN.
MIBELAS 24 FE vs OVULEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethinyl estradiol suppresses LH and FSH, primarily inhibiting ovulation; drospirenone is a progestin with anti-mineralocorticoid and anti-androgenic activity, increasing cervical mucus viscosity and altering endometrial morphology.
Ovulen is a combination oral contraceptive containing ethynodiol diacetate (a progestin) and mestranol (an estrogen). It inhibits ovulation by suppressing gonadotropin-releasing hormone (GnRH) from the hypothalamus, reducing luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the pituitary. It also increases cervical mucus viscosity and alters endometrial development, impeding sperm penetration and implantation.
One tablet orally once daily for 24 days followed by 4 placebo tablets. Each tablet contains 75 mcg desogestrel and 0.02 mg ethinyl estradiol.
1 tablet (1 mg ethynodiol diacetate, 50 mcg mestranol) orally once daily for 21 days, followed by 7 days of placebo or no medication.
None Documented
None Documented
Drospirenone: ~30 hours; Ethinyl estradiol: ~17 hours. Steady-state reached after ~10 days for drospirenone.
Ethinylestradiol: 10-20 hours (mean 17 hours); Dimethisterone: 10-15 hours. Clinical context: Steady state achieved after 3-5 days; elimination prolonged in hepatic impairment.
Drospirenone: 40-50% renal as metabolites, <10% unchanged; ~50% fecal. Ethinyl estradiol: ~40% renal, 60% fecal.
Renal: 50-60% as metabolites (glucuronide and sulfate conjugates), biliary/fecal: 40-50% (enterohepatic circulation).
Category C
Category C
Oral Contraceptive
Oral Contraceptive